5-MeO-DBT, also known as 5-methoxy-N,N-dibutyltryptamine, is a serotonin receptor modulator, and a rare substituted tryptamine derivative, which is thought to be a psychoactive substance.
Unlike many other related compounds it exhibits very low efficacy for the 5-HT<sub>2A</sub> receptor.
5-MeO-DBT was first described in the literature by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). It was encountered as a novel designer drug by 2019 and was assessed pharmacologically in 2023. The drug is controlled under drug analogue legislation in a number of jurisdictions.
In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin briefly mentioned 5-MeO-DBT and described it as a known compound with unknown activity. Relatedly, the properties and effects of 5-MeO-DBT are unknown. In any case, related drugs like dibutyltryptamine (DBT) and 4-HO-DPT have been reported to yield disappointing effects.
Based on limited evidence, 5-MeO-DBT acts as a non-selective serotonin receptor agonist with the highest potency and efficacy at the 5-HT<sub>1A</sub> receptor. It has a similar potency to 5-MeO-MiPT for this target. The substance, unlike many other substituted tryptamines, acts as a very weak and low efficacy partial agonist for the 5-HT<sub>2A</sub> receptor. Among the group of related tryptamine analogues it also displayed the lowest efficacy for the 5-HT<sub>2C</sub> receptor.
5-MeO-DBT decreased locomotor activity and failed to substitute for the discriminative stimulus effects of DOM in rodent drug discrimination tests.
Analogues of 5-MeO-DBT include dibutyltryptamine (DBT), 4-HO-DBT, 5-MeO-DMT, 5-MeO-DET, 5-MeO-DPT, 5-MeO-DiPT, 5-MeO-DALT, 5-MeO-DsBT, and 5-MeO-MBT, among others.
5-MeO-DBT was first described in the literature by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). It was encountered as a novel designer drug by 2019.
5-MeO-DBT was made schedule I at the state level in Alabama on September 13, 2024.